MedElevator Войти в исследования
← Поиск публикаций

DOI 10.15252/emmm.201506039

Медицинская библиотека · EMBO molecular medicine · 2016

CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.

Guan Yuting, Ma Yanlin, Li Qi, Sun Zhenliang, Ma Lie, Wu Lijuan, Wang Liren, Zeng Li, Shao Yanjiao, Chen Yuting, Ma Ning, Lu Wenqing, Hu Kewen, Han Honghui, Yu Yanhong, Huang Yuanhua, Liu Mingyao, Li Dali

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The X-linked genetic bleeding disorder caused by deficiency of coagulator factor IX, hemophilia B, is a disease ideally suited for gene therapy with genome editing technology. Here, we identify a family with hemophilia B carrying a novel mutation, Y371D, in the human F9 gene. The CRISPR/Cas9 system was used to generate distinct genetically modified mouse models and confirmed that the novel Y371D mutation resulted in a more severe hemophilia B phenotype than the previously identified Y371S mutation. To develop therapeutic strategies targeting this mutation, we subsequently compared naked DNA constructs versus adenoviral vectors to deliver Cas9 components targeting the F9 Y371D mutation in adult mice. After treatment, hemophilia B mice receiving naked DNA constructs exhibited correction of over 0.56% of F9 alleles in hepatocytes, which was sufficient to restore hemostasis. In contrast, the adenoviral delivery system resulted in a higher corrective efficiency but no therapeutic effects due to severe hepatic toxicity. Our studies suggest that CRISPR/Cas-mediated in situ genome editing could be a feasible therapeutic strategy for human hereditary diseases, although an efficient and clinically relevant delivery system is required for further clinical studies.

Для цитирования: Guan Yuting, Ma Yanlin, Li Qi, Sun Zhenliang, Ma Lie, Wu Lijuan, Wang Liren, Zeng Li, Shao Yanjiao, Chen Yuting, Ma Ning, Lu Wenqing, Hu Kewen, Han Honghui, Yu Yanhong, Huang Yuanhua, Liu Mingyao, Li Dali. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.. EMBO molecular medicine. 2016. DOI: 10.15252/emmm.201506039.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.